![]() Darglitazone structure
|
Common Name | Darglitazone | ||
---|---|---|---|---|
CAS Number | 141200-24-0 | Molecular Weight | 420.48100 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C23H20N2O4S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of DarglitazoneDarglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research[1]. |
Name | 5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
---|---|
Synonym | More Synonyms |
Description | Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research[1]. |
---|---|
Related Catalog | |
Target |
PPAR-γ |
In Vitro | In cell lines representing white (3T3-L1 and 3T3-F442A) and brown (HIB-1B) adipose tissues and skeletal muscle (L6), within 4 h of exposing these cells to 30 μM Darglitazone, there is an increase in uncoupling protein 2 (UCP2) mRNA which reached a plateau of 5-10 times the basal in about 8 h. Darglitazone can stimulate the expression of UCP2 gene probably via PPAR-γ[2]. |
In Vivo | Darglitazone treatment restores euglycemia and normalized elevated corticosterone, triglycerides, and very-low-density lipoprotein levels. Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24 h of recovery. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult[1]. Animal Model: Male diabetic ob/ob mice[1] Dosage: 1 mg/kg Administration: Oral administration; daily; for 7 days Result: Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice. |
References |
Molecular Formula | C23H20N2O4S |
---|---|
Molecular Weight | 420.48100 |
Exact Mass | 420.11400 |
PSA | 118.06000 |
LogP | 4.63550 |
Storage condition | -20℃ |
~78% Darglitazone CAS#:141200-24-0 |
Literature: Hulin, Bernard; Clark, David A.; Goldstein, Steven W.; McDermott, Ruth E.; Dambek, Paul J.; et al. Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1853 - 1864 |
~% Darglitazone CAS#:141200-24-0 |
Literature: Hulin, Bernard; Clark, David A.; Goldstein, Steven W.; McDermott, Ruth E.; Dambek, Paul J.; et al. Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1853 - 1864 |
Precursor 1 | |
---|---|
DownStream 0 |
5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-2,4-thiazolidinedione |
Darglitazone |
5-[4-[3-(2-phenyl-5-methyl-4-oxazolyl)propionyl]benzyl]thiazolidine-2,4-dione |
5-<4-<3-(5-methyl-2-phenyl-4-oxazolyl)propionyl>-benzyl>thiazolidine-2,4-dione |
Darglitazone [INN] |
[3H]Darglitazone |
5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]-thiazolidine-2,4-dione |
UNII-AVP9C03Z3K |